Health hub planned for former Boots store
An NHS health facility is planned for a former Boots store in Rotherham.
The proposals would transform the disused building on Effingham Street into a Town Centre Health Hub in two phases.
It would begin with the relocation of Abbey Pharmacy and have the potential to expand to offer a range of walk-in NHS services, according to Rotherham Council.
The authority acquired the site, which had stood empty since 2022, in May 2024 as part of plans to take over underused town centre properties for regeneration efforts.
Phase one of the project would see Abbey Pharmacy relocate from Howard Street, freeing up space ahead of redevelopment works at the Indoor Covered Market, due to begin in February 2026.
Phase two would involve refurbishing the rest of the three-storey building to accommodate GP and other health services, directly accessible to the public.
According to the Local Democracy Reporting Service, council officers have said they are already in talks with healthcare providers interested in occupying the space.
To pay for the works, the council proposes reallocating funds from the Pathfinder programme originally earmarked for a town centre music venue.
Around £1.3m would fund phase one, with a further £400,000 to support feasibility studies and detailed designs for the second phase.
The council hopes the project could ease pressure on existing NHS facilities and improve footfall in the town centre.
It has been inspired by a similar scheme in Barnsley, where a community diagnostic centre in the Glassworks has been credited with attracting extra visitors, additional spending and cutting levels of missed appointments due to its proximity to public transport.
The Health Select Commission will be updated on the plans ahead of Rotherham Council's cabinet formally considering the scheme on 7 July.
The commission will be asked to support the cabinet's expected recommendations to move forward with phase one, unlock the initial funding, and enter negotiations with interested health providers for the wider second phase.
Listen to highlights from South Yorkshire on BBC Sounds, catch up with the latest episode of Look North
Shopping centre health hub plan moves step closer
Outpatient services to move to shopping centre
Rotherham Council
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Councillors praise value of Castle Point community leisure centres after visit
Councillors have praised the value of community leisure centres in Castle Point following a recent visit. Castle Point councillors Tom Gibson and Rob Lillis toured Runnymede and Waterside Leisure Centres on Tuesday, June 17, alongside Shane Williams, assistant director for recreation. They explored the facilities, discussed future plans, and saw how the centres are supporting residents' health and wellbeing. Rob Lillis, councillor responsible for health, wellbeing and housing, said: "It was fantastic to see so many young people making the most of our leisure centres. "At a time when childhood obesity is on the rise, it's more important than ever to provide accessible, active spaces for all." Tom Gibson, councillor responsible for special projects and assets, said the centres play a key role in the community. He said: "We're proud of the work being done and excited about what's to come. "These centres are vital to the health and happiness of our residents."
Yahoo
43 minutes ago
- Yahoo
ESOT Congress 2025: Scientists create functional human islets in 3D printing breakthrough for type 1 diabetes treatment
LONDON, June 28, 2025 /PRNewswire/ -- A team of international scientists has made a major leap forward in diabetes research by successfully 3D printing functional human islets using a novel bioink. Presented today at the ESOT Congress 2025, the new technology could pave the way for more effective and less invasive treatment for people living with type 1 diabetes. The breakthrough involved printing human islets – the insulin-producing clusters of cells in the pancreas – using a customised bioink made from alginate and decellularised human pancreatic tissue. This approach produced durable, high-density islet structures that remained alive and functional for up to three weeks, maintaining strong insulin responses to glucose and showing real potential for future clinical use. Traditional islet transplants are typically infused into the liver, a process that can result in significant loss of cells and limited long-term success. In contrast, the 3D-printed islets were designed to be implanted just under the skin, a simple procedure requiring only local anaesthesia and a small incision. This minimally invasive approach could offer a safer and more comfortable option for patients. "Our goal was to recreate the natural environment of the pancreas so that transplanted cells would survive and function better," explained lead author Dr. Quentin Perrier. "We used a special bioink that mimics the support structure of the pancreas, giving islets the oxygen and nutrients they need to thrive." The bioprinted islets stayed alive and healthy, with over 90% cell survival. They responded better to glucose than standard islet preparations, releasing more insulin when it was needed. By day 21, the islets showed a stronger ability to sense and react to blood sugar levels – an important sign that they could work well after being implanted. The constructs maintained their structure without clumping or breaking down, overcoming a common hurdle in earlier approaches. Additionally, the 3D-printed structures featured a porous architecture that enhanced the flow of oxygen and nutrients to the embedded islets. This design helped maintain cell health and promoted vascularisation, both of which are critical for long-term survival and function after transplantation. "This is one of the first studies to use real human islets instead of animal cells in bioprinting, and the results are incredibly promising," noted Dr. Perrier. "We're getting closer to creating an off-the-shelf treatment for diabetes that could one day eliminate the need for insulin injections." View original content: SOURCE European Society for Organ Transplantation (ESOT) Congress 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Weight loss programme improves eating disorder symptoms
An intensive weight loss programme can improve eating disorder symptoms in people with type 2 diabetes. This is according to a University of Oxford study published in The Lancet Psychiatry. The research focuses on an intensive low-energy diet programme, similar to the NHS Type 2 Diabetes Path to Remission. Participants in the total diet replacement (TDR) programme showed significant improvements in their eating disorder symptoms, which persisted even six months after the programme concluded, despite some weight regain. This directly addresses a gap in research highlighted by recent National Institute for Health and Care Excellence (NICE) guidance on the psychological impact of restrictive diets. The lead author, Dr Elena Tsompanaki, a registered dietitian, said: "Our findings challenge the assumption that weight loss programmes worsen eating disorder symptoms in vulnerable people, potentially opening up important treatment options that many patients might have previously been denied." The study enlisted 56 participants with type 2 diabetes (diagnosed within the last six years), overweight or obesity, and existing eating disorder symptoms. Half of the participants were assigned to receive a low-energy (~860 kcal/day) TDR programme with behavioural support for six months, while the control group received usual diabetes care from their GPs. The study assessed four types of symptoms: restraint eating, eating concerns, shape concerns, and weight concerns. Key findings of the research show that eating disorder symptoms significantly improved in the TDR group compared to usual care at six months, with the benefit persisting at 12 months. The TDR group also saw significant reductions in depression and diabetes distress symptoms at six and 12 months compared to usual care. Crucially, no participants were suspected of developing a new eating disorder. Professor Susan Jebb, OBE, study author and professor of diet and population health, commented: "Our new findings provide reassurance that these programmes can be safely offered to patients with symptoms of eating disorders, providing an opportunity for them to benefit from these effective treatments." The study is important as there have been concerns that weight loss programmes, like the NHS Path to Remission, might not be safe or appropriate for people at high risk of eating disorders who might otherwise benefit from weight loss. Dr Dimitrios Koutoukidis, the senior author, added: "This study provides crucial reassurance that this type of intervention does not appear to harm, and may even benefit, people with type 2 diabetes already experiencing eating disorder symptoms. "It suggests that receiving structured support to lose weight may improve not only the physical health of this vulnerable group but also aspects of their mental health too." The study does acknowledge limitations, including the small sample size and participant demographics. The team, who worked with patient advisors throughout the study, are continuing to follow up participants to explore how their eating disorder symptoms change in the longer term.
